Metadichol ® and MRSA Infections: A Case Report

Abstract

Metadichol ® [1] is a Nanoemulsion of long-chain alcohols called as Policosanol and is present in foods such as rice, sugar cane, wheat, and peanuts. Metadichol ® acts on Nuclear Vitamin D receptors (VDR) that have a ubiquitous presence in cells and tissues of the body to stimulate the immune system and inhibit a variety of disease processes, resulting from viral, bacterial and parasitic infections. Infectious agents can cause disease by avoiding normal host defense mechanisms or by subverting them to promote their replication. They do so by blocking VDR receptor that is responsible for innate immunity, and this suppression of the immune response leads to persistent infections. We present a case study of a patient who had acquired MRSA infections and how Metadichol ® by its actions on the VDR has resolved the problem of this deadly disease without any side effects.

Full text

Metadichol® and MRSA Infections: A Case Report
PR Raghavan*
Nanorx Inc, PO Box 131, Chappaqua, NY 10514, USA
*Corresponding author: PR Raghavan, Nanorx Inc, PO Box 131, Chappaqua, NY 10514, USA, E-mail: raghavan@nanorxinc.com
Received date: April 17, 2017; Accepted date: April 21, 2017; Published date: April 24, 2017
Copyright: © 2017 Raghavan. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Metadichol® [1] is a Nanoemulsion of long-chain alcohols called as Policosanol and is present in foods such as
rice, sugar cane, wheat, and peanuts. Metadichol® acts on Nuclear Vitamin D receptors (VDR) that have a
ubiquitous presence in cells and tissues of the body to stimulate the immune system and inhibit a variety of disease
processes, resulting from viral, bacterial and parasitic infections. Infectious agents can cause disease by avoiding
normal host defense mechanisms or by subverting them to promote their replication. They do so by blocking VDR
receptor that is responsible for innate immunity, and this suppression of the immune response leads to persistent
infections.
We present a case study of a patient who had acquired MRSA infections and how Metadichol® by its actions on
the VDR has resolved the problem of this deadly disease without any side effects.
Keywords: VDR; Vitamin D; Metadichol®; Innate immunity; MRSA;
Inverse agonist; Protean agonist; Nanoemulsion; Lipid alcohols
Introduction
Methicillin-resistant
Staphylococcus aureus
(MRSA) is a major
problem hospitals, healthcare facilities, Globally two billion people are
estimated to carry some form of
S. aureus
; of these, up to 60 million
(approximately 3 % of carriers) are thought to carry MRSA [2].
Bacteria and other pathogens ght back by acquiring resistance to
drugs rapidly. is resistance has led to the emergence of antibiotic-
resistant superbugs. It is projected that ten million lives a year will be
lost by 2050. It will also have an increasing cost of 100 trillion USD,
more than one and a half times the annual world GDP today, or
roughly the equivalent of losing the UK economy from global output
every year. It has been estimated that in USA about 1.7 million
nosocomial infections occurred in 2002, with 99,000 associated deaths
[3,4]. e incidence is 4.5 nosocomial infections per 100 admissions,
with direct costs (at 2004 prices) ranging from $10,500 per case (for
bloodstream, urinary tract, or respiratory infections in
immunocompetent patients) to $111,000 per case for antibiotic-
resistant infections in the blood in patients with transplants. Total
direct costs of nosocomial infections are $17 billion, in U.S and about
$75 billion worldwide.
MRSA multi-drug resistant bacterial pathogens are causing serious
community and hospital-acquired infections much of it as skin and
so tissue infections, bone, joint and implant infections, ventilator-
associated pneumonia, and sepsis. MRSA can be transmitted from
person to person via skin or the sharing of contaminated objects [5].
e current research in search of new agents is to modify and do some
minor tweaks of existing antibiotics which already have infectious
agents that have developed resistance to it. ere is a need for new
antibacterial molecules that can treat infections caused by MRSA [6].
Case Presentation
Patient Male early 40’s was diagnosed with a CA-MRSA
(community associated methicillin-resistant
Staphylococcus aureus
)
nger infection. A culture from the infection was sent for pathology
analysis, but the patient began use of Metadichol at a dosage of 5 mg
twice day topically on the wound while waiting for the lab result. e
result conrmed the diagnosis as CA-MRSA, and an oral antibiotic
(clindamycin, generic for Cleocin) was prescribed. e patient did not
use the antibiotic but instead continued with its use topically for
infection as well as pain (as an alternative to hydrocodone).
He reported that the pain eased aer two days and had a complete
clearance of infection seen aer a week (Figure1). He continued to use
it topically on the wound for an additional 6 weeks, and the injury
cleared up completely. He did not use the antibiotics, and aer four
years he is disease free.
Discussion
Staphylococcus aureus
, typically resides in the nose but is also found
on the skin and in the gastrointestinal tract. Although its presence in
humans does not lead to disease, the risk is higher in those who are
carriers of
S. aureus
. Skin and so-tissue infections are common in this
population and can lead to more severe diseases like sepsis [7,8]. Also,
S. aureus
can cause pneumonia, osteomyelitis, infectious arthritis,
abscesses in many organ tissues and infections of surgical wounds or
prosthetic materials. A key feature of
S. aureus
disease is its recurrence,
which occurs for 8-33% of the cases [9]. Prior infection to
S. aureus
does not protect against subsequent infection. People with an elevated
risk for staphylococcal infection are low-birth-weight infants, children,
the elderly and patients with indwelling catheters, medical
implantation of devices, hemodialysis, diabetes or undergoing
immunosuppressive or cancer therapy.
Journal of Infectious Diseases and
Therapy Raghavan, J Infect Dis Ther 2017, 5:2
DOI: 10.4172/2332-0877.1000317
Case Report OMICS International
J Infect Dis er, an open access journal
ISSN:2332-0877
Volume 5 • Issue 2 • 1000317

Figure 1: A complete clearance of infection seen aer a week with Metadichol.
Vitamin D plays a signicant role in mediating immune function by
up-regulating the antibacterial immune response and thereby
preventing
S. aureus
colonization. MRSA-infected patients have lower
serum vitamin D levels than non-MRSA infected patients [10]. People
with 25-hydroxy vitamin D levels above 30 ng/ml were 50% less likely
to be
S. aureus
carriers. It is likely that vitamin D supplementation may
reduce the incidence of methicillin sensitive and methicillin resistant
Staphylococcal aureus
infections.
e Immune systems have developed mechanisms to neutralize and
remove pathogenic bacteria. In turn, bacteria have evolved
mechanisms to alter and evade the host immune response [11].
Pathogens slow the innate immune defenses by down-regulating the
VDR. [12-14]. For example
Mycobacterium tuberculosis
,
Mycobacterium Leprae
, and
Aspergillus
Fumigate
down-regulate VDR
activity. is action allows intracellular bacteria to persist in the
cytoplasm of nucleated cells and increases susceptibility to other
diseases [15]. Bacteria also exploit signaling cascades to initiate airway
inammation. Staphylococcal protein signaling through TNFR1, plays
a central role in the pathogenesis of
S. aureus
[16].
e likely mechanism of how Metadichol works is in its actionably
acting on the vitamin D receptor. We have shown that Metadichol
binds to the VDR and acts as an inverse but more likely as a protean
agonist [17]. It could competitively displace the bacteria and restore
normal VDR transcription activity of producing antimicrobial peptides
against the pathogens [18]. Metadichol is a TNF-alpha inhibitor, and
prevents the pathogenesis of
S. aureus
through the TNF alpha signaling
pathway [1].
MRSA strains that have become resistant to vancomycin, the last
drug to which the organism had been uniformly sensitive, raises the
stakes in combating this disease. Metadichol by activating the VDR
inhibiting TNF alpha, serves as a key that ts many locks and works
through multiple pathways. us it fullls the need that many disease
states require action through multiple pathways to be ecacious.
Metadichol has the potential to serve as an anti-bacterial molecule
with a broad spectrum of activity, particularly given that it has
demonstrated no toxicity at doses of up to 5000 mg/kg [19-21].
Conclusion
Metadichol could be a novel OTC supplement and also as a far more
ecient substitute to prescription drugs, which have been largely
ineective in infectious diseases [22,23] and have many side eects
that add to health care costs. Given its overall safety, it is ready for large
scale testing in areas where infectious diseases are rampant.
References
1. Raghavan PR (2017) US patents 8,722,093 (2014) and 9,006,292 (2015).
2. http://amr-review.org/publications.
3. Klevens RM, Edwards JR, Richards CL Jr, Horan TC, Gaynes RP, et al.
(2007) Estimating health care-associated infections and deaths in U.S.
hospitals, 2002. Public Health Rep 122: 160-166.
4. Lindsay JA, Holden MT (2004) Staphylococcus aureus: superbug, super
genome. Trends Microbiol 18: 378-385.
Citation: Raghavan PR (2017) Metadichol® and MRSA Infections: A Case Report. J Infect Dis Ther 5: 317. doi:10.4172/2332-0877.1000317
Page 2 of 3
J Infect Dis er, an open access journal
ISSN:2332-0877
Volume 5 • Issue 2 • 1000317

5. Holcomb HG, Durbin KJ, Cho M, Choi KJ, Darling ND, et al. (2008)
Methicillin-resistant Staphylococcus aureus as a threat to public health: a
cellular approach. Georgetown Univ J Health Sci 5: 2.
6. Braine T (2011) Race against time to develop new antibiotics. Bull World
Health Organ 89: 88-89.
7. Van Belkum A, Melles DC, Nouwen J, van Leeuwen WB, van Wamel W,
et al. (2009) Coevolutionary aspects of human colonization and infection
by Staphylococcus aureus. Infect Genet Evol 9: 32-47.
8. David MZ, Daum RS (2010) Community associated methicillin-resistant
Staphylococcus aureus: epidemiology and clinical consequences of an
emerging epidemic. Clin Microbiol Rev 23: 616-687.
9. Kallen AJ, Mu Y, Bulens S, Reingold A, Petit S, et al. (2010) Health care-
associated invasive MRSA infections, (2005–2008). JAMA 304: 641-648.
10. Matheson EM, Mainous AG 3rd, Hueston WJ, Diaz VA, Everett CJ (2010)
Matheson EM. Scand J Infect Dis 42: 455-460.
11. Dermine JF, Desjardins M (1999) Survival of intracellular pathogens
within macrophages. Protop 210: 11-24.
12. Xu Y, Xie J, Li Y, Wang H (2003) using a cDNA microarray to study
cellular gene expression altered by Mycobacterium tuberculosis. Chin
Med J 116: 1070-1073.
13. Liu PT, Wheelwright M, Teles R, Komisopoulou E, Edfeldt K, et al. (2012)
MicroRNA-21 targets the vitamin D-dependent antimicrobial pathway in
leprosy. Nat Med 18: 267-273.
14. Coughlan CA, Chotirmall SH, Renwick J, Hassan T, Low TB, et al. (2012)
e eect of Aspergillus fumigatus infection on vitamin D receptor
expression in cystic brosis. Am J Respir Crit Care Med 186: 999-1007.
15. Marks R, Allegrante JP (2002) Comorbid disease proles of adults with
end-stage hip osteoarthritis. Med Sci Monit 8: CR305-CR309.
16. Gomez MI, Lee A, Reddy B, Muir A, Soong G, et al. (2004)
Staphylococcus aureus protein A induces airway epithelial inammatory
responses by activating TNFR1. Nat Med 10: 842-848.
17. Neubig RR (2007) Missing Links Mechanisms of Protean Agonism, Mol
Pharmaco 71: 1200-1202.
18. Mangin M, Sinha R, Fincher K (2014) Inammation and vitamin D: the
infection connection. Inamm Res 63: 803-819
19. Alemán CL, Más R, Hernández C, Rodeiro I, Cerejido E, et al. (1994) A
12-month study of policosanol oral toxicity in Sprague Dawley rats.
Toxicol Lett 70: 77-87.
20. Alemán CL, Más Ferreiro, Noa Puig M, Rodeiro Guerra I, Hernández
Ortega C, et al. (1994) Carcinogenicity of policosanol in Sprague-Dawley
rats: A 24-month study. Teratog Carcinog Mutagen 14: 239-249.
21. Aleman, CL, Puig MN, Elías EC, Ortega CH, Guerra IR, et al. (1995)
Carcinogenicity of policosanol in mice: An 18-month study. Food Chem
Toxicol 33: 573-578.
22. Raghavan PR (2016) In vitro Inhibition of Zika Virus by Metadichol®. A
Novel Nano Emulsion Lipid. J Immunol Tech Infect Dis 5: 4.
23. Raghavan PR (2016) Inhibition of Dengue and other enveloped viruses by
Metadichol®, a Novel Nanoemulsion Lipid, Journal of the of Science of
Healing Outcomes 8: 19-25.
Citation: Raghavan PR (2017) Metadichol® and MRSA Infections: A Case Report. J Infect Dis Ther 5: 317. doi:10.4172/2332-0877.1000317
Page 3 of 3
J Infect Dis er, an open access journal
ISSN:2332-0877
Volume 5 • Issue 2 • 1000317